PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50325C00004 — BULK PHARMA - GROUP B (ASSET MGMT) ACYCLOVIR SODIUM SOLUTION, DOXYCYCLINE INJ., MEROPENEM, SODIUM CHLORIDE, STERILE WAT…

BULK PHARMA - GROUP B (ASSET MGMT) ACYCLOVIR SODIUM SOLUTION, DOXYCYCLINE INJ., MEROPENEM, SODIUM CHLORIDE, STERILE WAT… is a federal NONE award for Department of Health and Human Services (HHS) held by FRESENIUS KABI, LLC. Estimated value $86.3M ($86.3M obligated). Current period of performance ends Mar 13, 2030. Last award drew 5 bidders. Place of performance: LAKE ZURICH, IL.

$86.3M
Estimated Value
Mar 13, 2030
PoP End / Expires
5
Bidders (last award)

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See related expiring contracts →

Analysis

Public

FRESENIUS KABI, LLC holds $91.7M across 1,477 federal awards, concentrated at Department of Health and Human Services (HHS). Competition previously drew 5 offers. Set-aside status: NONE. Recompete timing centers on the Mar 13, 2030 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

NONE
Contract number75A50325C00004
AgencyDepartment of Health and Human Services (HHS)
IncumbentFRESENIUS KABI, LLC
UEIC2TRNWNQKMD6
NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505
Place of performanceLAKE ZURICH, IL
PoP end (current)Mar 13, 2030
Obligated$86.3M

BULK PHARMA - GROUP B (ASSET MGMT) ACYCLOVIR SODIUM SOLUTION, DOXYCYCLINE INJ., MEROPENEM, SODIUM CHLORIDE, STERILE WATER

Recompete timing

Public
Expiring in 1305 days

Current PoP ends Mar 13, 2030 (1305 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Sep 13, 2028.

Watch this contract — one email →

Incumbent footprint

Public record

FRESENIUS KABI, LLC$91.7M obligated across 1,477 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($91.7M) · all agencies
Department of Health and Human Services (HHS)$86.2M · 94%Department of Defense (DOD)$5.5M · 6%
Open full company profile

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

More in SCOUT
Track this contract →

Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open FRESENIUS KABI, LLC’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract 75A50325C00004?

75A50325C00004 (BULK PHARMA - GROUP B (ASSET MGMT) ACYCLOVIR SODIUM SOLUTION, DOXYCYCLINE INJ., MEROPENEM, SODIUM CHLORIDE, STERILE WAT…) is a Department of Health and Human Services (HHS) award with an estimated value of $86.3M, currently held by FRESENIUS KABI, LLC. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on 75A50325C00004?

FRESENIUS KABI, LLC is the incumbent with $91.7M across 1477 related awards in SCOUT’s public footprint. The current period of performance ends Mar 13, 2030.

When does 75A50325C00004 come up for recompete?

SCOUT tracks a period-of-performance end of Mar 13, 2030. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75A50325C00004